ArticleJournal of thoracic disease2026
Noninvasive prediction of ALK fusion status in non-small cell lung cancer by a machine learning model combining CT images and clinical information.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the primary contributor to global cancer mortality, lung cancer requires precise anaplastic lymphoma kinase (ALK) genotyping to implement personalized targeted treatment for non-small cell lung cancer (NSCLC) patients. Invasive biopsy-based ALK detection is clinically limited by sampling deviation, procedural complications, and insufficient tumor specimens. The objective of this study was to develop and validate a machine learning model that integrates computed tomography (CT) radiomics features with clinicopathological data to non-invasively predict ALK fusion status in patients with NSCLC. Methods: This retrospective multi-center study enrolled 722 NSCLC patients (291 ALK-positive, 431 ALK-negative). From segmented tumor regions, 2,264 radiomics features were derived. After feature selection using the least absolute shrinkage and selection operator (LASSO) regression, three predictive models were constructed and compared: a clinical & region of interest (ROI) model, a radiomics model, and a combined model integrating both feature types. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity in training, test, and validation cohorts. Results: The final models included 14, 67, and 53 features in the clinical & ROI model, radiomics model, and combined model, respectively. The combined model demonstrated superior predictive performance, achieving an AUC of 0.997 in the training cohort, 0.988 in the test cohort, and 0.973 in the validation cohort. It significantly outperformed the clinical & ROI model (AUC: 0.997 Conclusions: A machine learning model combining CT radiomics and clinical data exhibited robust performance in predicting ALK fusion status in NSCLC patients. This non-invasive approach shows significant potential as a clinical tool for pre-therapeutic selection of patients who may benefit from ALK-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.